MedTrace Logo

Comparing ARNI With ACE Inhibitor on Endothelial Function

NCT03119623 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2018-10-11

No results posted yet for this study

Summary

PARADOR is multisite, randomized, double-blind, phase IV clinical trial to compare the effect of sacubitril/valsartan (Entresto™) to enalapril (Vasotec®) on blood vessel function in subjects with heart failure with reduced ejection fraction (HFREF).

Conditions

  • Heart Failure With Reduced Ejection Fraction

Interventions

DRUG

sacubitril/valsartan

Sacubitril/valsartan 100mg titrated up to sacubitril/valsartan 200mg

DRUG

Enalapril

enalapril 5mg, titrated up to 10mg po BID

Sponsors & Collaborators

Principal Investigators

  • Orly Vardeny, PharmD, MS · University of Wisconsin, Madison

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2019-08-31
Completion
2019-08-31
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03119623 on ClinicalTrials.gov